Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
The TKI combination reported clinical activities in patients with advanced <i>EGFR</i>-mutant LUAD resistant to EGFR TKIs and mild toxicity in those with MET overexpression.
Authors
- Cheng-Hsiang Chu (ORCID: https://orcid.org/0000-0002-4495-8785)
- Zhe-Rong Zheng
- Tse-Hsien Lo
- Gee‐Chen Chang (ORCID: https://orcid.org/0000-0002-1802-417X)
- Kun-Chieh Chen
- Jia-Jun Wu
Institutions
- National Chung Hsing University (TW)
- Chung Shan Medical University Hospital (TW)
- Chung Shan Medical University (TW)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100832
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministry of Health and Welfare
- Chung Shan Medical University Hospital